Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Clinical Immunology

Long-Term Monitoring and Surveillance

At a Glance

NFKB1-related immune dysregulation can change with age, so follow-up is individualized rather than fixed. Regular immunology visits, blood counts, immunoglobulin testing, immune-cell tracking, and selected cancer or EBV checks help guide care for patients and variant-positive relatives.

Living with NFKB1-related immune dysregulation is a marathon, not a sprint. Because the condition is age-dependent, your immune system can evolve over time [1]. Long-term management often utilizes “watchful waiting”—a proactive strategy of regular check-ups and screenings tailored to your phenotype to catch changes in your immune health before they become serious [2].

A Proactive Surveillance Schedule

While there is no single “official” universal schedule just for NFKB1, most specialists individualize established guidelines for Common Variable Immunodeficiency (CVID) and similar disorders [2].

  • Annual Immunology Review: Periodic visits to your immunologist for a complete physical exam to check for an enlarged spleen or lymph nodes.
  • Routine Labs: You may need bloodwork periodically, including a Complete Blood Count (CBC) to monitor for autoimmunity and quantitative immunoglobulins. (Note: quantitative IgG while receiving IgRT is partly donor-derived).
  • Immunophenotyping: This specialized test (flow cytometry) tracks your B-cell and T-cell “subsets.” Tracking the “trend” over time helps individualize care decisions [3][4].
  • EBV Monitoring: Because of the risk of EBV-associated lymphoproliferative disease, your doctor may periodically check your blood for the presence of the Epstein-Barr Virus (EBV) if indicated by symptoms or immunosuppressive treatment [5][6].

Understanding and Managing Malignancy Risks

Research into large referral cohorts of symptomatic patients with NFKB1 variants observed a malignancy (cancer) rate of approximately 16.8% [1]. It is important to remember that this data comes from selected groups of people who were often diagnosed because they were already sick; it does not represent an exact, universal lifetime prediction for every individual [1].

The most common concerns in these populations include:

  • Lymphoma: Cancers of the lymphatic system are frequently reported. Monitoring involves watching for “B-symptoms” like night sweats or rapidly growing lymph nodes [7][8]. (Note: enlarged lymph nodes and fatigue have many infectious or inflammatory causes and do not automatically mean cancer).
  • Gastric (Stomach) Health: Because the NFKB1 pathway is vital for the lining of the gut, there is a recognized risk for gastric cancer [9]. Current CVID expert consensus suggests adult decisions regarding a baseline upper endoscopy with biopsies, followed by monitoring for Helicobacter pylori, should be individualized based on symptoms, family history, and local guidelines [2]. Ensure you continue routine age-appropriate cancer screening.

Monitoring for Asymptomatic Family Members

If a family member tests positive for the pathogenic NFKB1 variant but feels perfectly healthy, they are considered a variant-positive individual. “Asymptomatic” does not guarantee lifelong absence of symptoms.

Studies have shown that some carriers—even those who never get sick—show subtle abnormalities in their immune bloodwork, such as altered T-cell counts or reduced memory B-cells [4]. Because the condition’s presentation is age-dependent, someone who is healthy at age 20 may develop immune changes at age 40 [3]. For this reason, variant-positive individuals should have genetic counseling and an individualized baseline immune evaluation to guide their follow-up [3][4].

Coping with “Scanxiety” and the Psychological Toll

The burden of constant monitoring can lead to scanxiety—the intense stress and anxiety that occurs before and after medical tests. People with inborn errors of immunity often report lower scores in emotional and social health due to the weight of their diagnosis [10].

To manage this burden:

  • Structured Transitions: If you are moving from pediatric to adult care, a structured transition plan can significantly lower the emotional burden [11].
  • Shared Decision-Making: You and your doctor should work as partners. If a specific screening feels too frequent or overwhelming, talk about the risks and benefits to find a schedule that feels manageable for your life [12].
  • Psychosocial Support: Many patients find relief in working with a therapist who specializes in chronic illness or joining rare-disease support groups to share experiences with others navigating similar surveillance [13][14].

Regular monitoring is not just about looking for “bad news”; it is about giving you and your doctors the data needed to keep you healthy, active, and in control of your future [12].

Common questions in this guide

How often should NFKB1-related immune dysregulation be monitored?
There is no single schedule for everyone with NFKB1-related immune dysregulation. Annual or periodic immunology reviews are often combined with blood tests and other screening, with timing adjusted for symptoms, immune findings, treatments, and changes over time.
What blood tests help track NFKB1-related immune dysregulation?
Monitoring may include a complete blood count, quantitative immunoglobulins, and flow cytometry, a specialized test that measures B-cell and T-cell subsets. Trends over time are often more useful than a single result, and IgG results may partly come from donor antibodies if you receive immunoglobulin replacement therapy.
Does NFKB1-related immune dysregulation increase the risk of cancer?
Selected studies of symptomatic people referred to specialty centers reported cancer in about 16.8%, but this figure is not a universal lifetime prediction for every person with an NFKB1 variant. Follow-up may focus on warning signs of lymphoma, stomach health, and routine age-appropriate cancer screening, with decisions tailored to individual risk.
Should a healthy family member with a pathogenic NFKB1 variant have follow-up?
Yes. Genetic counseling and a baseline immune evaluation can help identify subtle changes and create an individualized follow-up plan, even when the person feels well. Immune findings can change with age, so being symptom-free at one point does not guarantee they will remain unchanged.
When are EBV testing and an upper endoscopy considered?
EBV blood testing may be considered when symptoms or immunosuppressive treatment raise concern for EBV-associated complications. In adults, a baseline upper endoscopy with biopsies and checks for Helicobacter pylori may be considered based on symptoms, family history, and local guidance rather than automatically for everyone.
How can I cope with anxiety about repeated monitoring?
Shared decision-making can help you and your doctor prioritize the tests that matter most for your immune profile and agree on a manageable schedule. When relevant, a structured transition between pediatric and adult care, counseling for chronic illness, or a rare-disease support group may also reduce the emotional burden.

Get notified when new evidence is published on NFKB1-related immune dysregulation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.

    Lorenzini T, Fliegauf M, Klammer N, et al.

    The Journal of allergy and clinical immunology 2020; (146(4)):901-911 doi:10.1016/j.jaci.2019.11.051.

    PMID: 32278790
  2. 2

    Multidisciplinary Delphi consensus on malignancy screening in patients with common variable immunodeficiency.

    Cabanero-Navalon MD, de Andrés-Martín A, Gil AA, et al.

    Frontiers in immunology 2026; (17()):1897051 doi:10.3389/fimmu.2026.1897051.

    PMID: 42676356
  3. 3

    Vulnerability to Meningococcal Disease in Immunodeficiency Due to a Novel Pathogenic Missense Variant in NFKB1.

    Anim M, Sogkas G, Schmidt G, et al.

    Frontiers in immunology 2021; (12()):767188 doi:10.3389/fimmu.2021.767188.

    PMID: 35003082
  4. 4

    Clinical and immunological characterization of NFKB1 haploinsufficiency in Japan.

    Moriya K, Kamiyama Y, Ogino R, et al.

    Frontiers in immunology 2026; (17()):1866459 doi:10.3389/fimmu.2026.1866459.

    PMID: 42488646
  5. 5

    NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.

    Boztug H, Hirschmugl T, Holter W, et al.

    Journal of clinical immunology 2016; (36(6)):533-40 doi:10.1007/s10875-016-0306-1.

    PMID: 27338827
  6. 6

    Human NF-κB1 Haploinsufficiency and Epstein-Barr Virus-Induced Disease-Molecular Mechanisms and Consequences.

    Hoeger B, Serwas NK, Boztug K

    Frontiers in immunology 2017; (8()):1978 doi:10.3389/fimmu.2017.01978.

    PMID: 29403474
  7. 7

    Late-Onset Antibody Deficiency Due to Monoallelic Alterations in NFKB1.

    Schröder C, Sogkas G, Fliegauf M, et al.

    Frontiers in immunology 2019; (10()):2618 doi:10.3389/fimmu.2019.02618.

    PMID: 31803180
  8. 8

    Common Variable Immunodeficiency-Associated Cancers: The Role of Clinical Phenotypes, Immunological and Genetic Factors.

    Bruns L, Panagiota V, von Hardenberg S, et al.

    Frontiers in immunology 2022; (13()):742530 doi:10.3389/fimmu.2022.742530.

    PMID: 35250968
  9. 9

    Loss of NF-κB1 Causes Gastric Cancer with Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT-1-Dependent Manner.

    O'Reilly LA, Putoczki TL, Mielke LA, et al.

    Immunity 2018; (48(3)):570-583.e8 doi:10.1016/j.immuni.2018.03.003.

    PMID: 29562203
  10. 10

    Health-related quality of life in patients with inborn errors of immunity: A systematic review and meta-analysis.

    Xiao N, Huang X, Yang D, et al.

    Preventive medicine 2024; (186()):108079 doi:10.1016/j.ypmed.2024.108079.

    PMID: 39053518
  11. 11

    Patient and caregiver perspectives on transition from pediatric to adult care in inborn errors of immunity: a Polish multicenter survey.

    Będzichowska A, Tomaszewska A, Napiórkowska-Baran K, et al.

    Frontiers in immunology 2026; (17()):1816943 doi:10.3389/fimmu.2026.1816943.

    PMID: 42433362
  12. 12

    Shared Decision-Making and Health-Related Quality of Life in the Diagnosis and Management of Patients With Inborn Errors of Immunity.

    Lawrence MG, Kim VHD, Orange JS, Scherzer R

    The journal of allergy and clinical immunology. In practice 2026; doi:10.1016/j.jaip.2026.07.010.

    PMID: 42447994
  13. 13

    "It's a Godsend": Parental experiences of genomic testing for paediatric inborn errors of immunity.

    Clark A, DeBortoli E, Blancoe M, et al.

    European journal of human genetics : EJHG 2025; (33(10)):1342-1349 doi:10.1038/s41431-025-01917-7.

    PMID: 40730688
  14. 14

    Genetic Counseling in Pediatric Inborn Errors of Immunity: Perspective Piece on Current Practice and Considerations.

    DeBortoli E, McInerney-Leo A, Macintosh R, et al.

    The journal of allergy and clinical immunology. In practice 2025; (13(8)):1918-1927 doi:10.1016/j.jaip.2025.03.052.

    PMID: 40252833

This page explains long-term surveillance for NFKB1-related immune dysregulation for informational purposes only and does not replace medical advice. Your immunologist and care team should tailor tests and timing to your symptoms, variant, and treatment.